Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

11 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-08-31

Study Completion Date

2015-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Standard treatment for kidney cancer is to remove the tumors from the body with surgery. The purpose of this clinical trial is to collect, preserve, and store excess kidney cancer tumor specimens that would normally be discarded after surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Ancillary Pilot Trial Using Whole Genome Sequencing In Patients With Advance Refractory Cancer

NCT01443390

Advanced Cancer

COMPLETED

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

NCT05334069

Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Ann Arbor Stage I Lymphoma +59 more

RECRUITING

Collection of Retrospective (Archival) Samples and Prospective Collection of Surplus Tissue and Blood Samples

NCT02239575

Cancer

WITHDRAWN

RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)

NCT02026960

Metastatic Renal Cell Carcinoma Genitourinary Cancer (Bladder, Prostate or Testicular)

TERMINATED NA

Collection Of Tissue, Blood, and Other Specimens From Patients With Head and Neck Tumors To Study the Causes, Diagnosis, Prevention and Treatment of Cancers

NCT00580203

Head and Neck Cancers

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this non-treatment, non-interventional protocol is to collect, preserve, and store excess tumor specimens, which would otherwise be discarded, following routine nephrectomy for subjects with advanced renal cell carcinoma (RCC). The collected tumor specimen will be preserved under current Good Manufacturing Practice conditions and will not be used for any other research or therapeutic purpose without a separate consent from the subject, specific to the intended use on a separate Institutional Review Board or Institutional Ethics Committee approved Argos sponsored study.

Following routine nephrectomy (partial or cytoreductive) as indicated for subjects with advanced RCC, small samples of the excised tumor will be sectioned and placed into an RNA preservative solution as supplied by the sponsor. After collection, this preserved tumor specimen will be shipped to a repository operating under current Good Manufacturing Practice conditions. The tumor specimen will be stored for no longer than five years unless subsequent consent is obtained for extended storage or other use.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Cancer Renal Cell Carcinoma Advanced Renal Cell Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Age ≥ 18 years
* 2\. Diagnosis or clinical signs of advanced RCC (Stage III or IV RCC; Refer to Appendix A)
* 3\. Scheduled for cytoreductive or partial (unilateral or bilateral) nephrectomy
* 4\. Signed and dated informed consent document indicating that the subject (or legally acceptable representative) has been informed of all pertinent aspects of tumor specimen collection prior to enrollment

Exclusion Criteria

* 1\. Evidence of brain metastases prior to nephrectomy
* 2\. Requirement for systemic chronic immunosuppressive drugs or systemic chronic corticosteroids, for active autoimmune disorder(s) or other conditions (e.g.: rheumatoid arthritis, systemic lupus erythematous, multiple sclerosis, organ transplant recipient, etc.)
* 3\. History of HIV infection, or history of chronic infection with Hepatitis B or Hepatitis C

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No